Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs

Rhea-AI Filing Summary

Kosuri Sri reported acquisition or exercise transactions in this Form 4 filing.

Ginkgo Bioworks Holdings, Inc. director Sri Kosuri received a grant of 25,000 restricted stock units on June 11, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of the company’s Class A common stock. The RSUs will vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date, provided Kosuri continues to serve as a non-employee director through that vesting date. This is a stock-based award, not an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kosuri Sri

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	25,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 25,000 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date.

Key Figures

RSUs granted: 25,000 RSUs Underlying shares: 25,000 shares Shares after transaction: 25,000 derivative units +1 more

4 metrics

RSUs granted 25,000 RSUs Grant on June 11, 2026 to non-employee director

Underlying shares 25,000 shares Class A Common Stock underlying the RSUs

Shares after transaction 25,000 derivative units Total RSUs held following the grant

Vesting date June 11, 2027 Latest possible vesting date, or earlier before next annual meeting

Key Terms

Restricted Stock Units, Class A Common Stock, Amended and Restated Non-Employee Director Compensation Program, vest

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Common Stock financial

"to receive one share of the Issuer's Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Amended and Restated Non-Employee Director Compensation Program financial

"In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program"

vest financial

"the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 05:04 PM Accepted by SEC EDGAR 06/15/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kosuri Sri

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/11/2026		A		25,000		(2)	(2)	Class A Common Stock	25,000	(1)	25,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date.

Remarks:

	/s/ Karen Tepichin, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Ginkgo Bioworks (DNA) director Sri Kosuri report in this Form 4?

Sri Kosuri reported receiving 25,000 restricted stock units as equity compensation. These RSUs are a grant, not a market purchase, and each can convert into one share of Class A common stock if vesting conditions are met.

How many RSUs did Sri Kosuri receive from Ginkgo Bioworks (DNA)?

Sri Kosuri received 25,000 restricted stock units. Each RSU represents a contingent right to one share of Class A common stock, giving him a potential future equity interest subject to vesting conditions and continued board service.

When do Sri Kosuri’s RSUs at Ginkgo Bioworks (DNA) vest?

The RSUs vest on the earlier of June 11, 2027, or the day immediately before the next annual meeting after grant. Vesting is conditioned on Kosuri’s continued service as a non-employee director through the applicable vesting date under the company’s program.

Is this Ginkgo Bioworks (DNA) Form 4 a stock purchase by Sri Kosuri?

No, this Form 4 reflects a grant of restricted stock units, not an open-market stock purchase. The RSUs were awarded at no cash cost as part of non-employee director compensation, with future delivery of shares subject to vesting conditions.

What does each RSU granted to Sri Kosuri by Ginkgo Bioworks (DNA) represent?

Each RSU represents a contingent right to receive one share of Class A common stock. Actual share delivery occurs only if the RSUs vest under the terms of the non-employee director compensation program and service conditions are satisfied.